Chula Licenses Thai PD-1 Antibody to US Biopharma
August 6, 2025
Chula Licenses Thai PD-1 Antibody to US Biopharma
In a historic first, Chulalongkorn University has licensed its novel Thai-developed PD-1 antibody to US-based OncoSynergy for next-generation cancer immunotherapy development.